



ZFW

I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature
and Deposit: August 18, 2004

Carl R. Schwartz, Reg. No. 29,437

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Majed M. Hamawy
Serial No.: 10/787,421
Filed: February 26, 2004
Title: MARKER PROTEINS FOR DIAGNOSING SMOOTH MUSCLE
CELL ABNORMALITIES
Art Unit: 1615

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement pursuant to 37 C.F.R. 1.97 and 1.98, and in particular Rule 97(b)(3). Since Applicant is unaware of any Office Action on the merits having issued, no additional fee is believed necessary for consideration of the enclosed art. However, if an Office Action on the merits has already issued, please consider this a submission under Rule 97(c)(2), and please then charge the required fee (believed to be \$180), plus any other needed fees, to Deposit Account 17-0055.

1. List

The attached form PTO-1449 constitutes the required list relating to the additional publications being submitted herewith for consideration by the Office. Applicant specifically reserves the right to consider swearing behind any reference not published more than one year prior to the effective filing date.

2. Copies

Attached hereto are legible copies of each item listed on the enclosed form PTO-1449.

Respectfully submitted,


Majed M Hamawy

Dated: August 18, 2004

By:

Carl R. Schwartz, Esq.
Reg. No.: 29,437
QUARLES & BRADY LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202
(414) 277-5715

MKE\5620796



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>					
Sheet	1	of	1	Attorney Docket Number	960296.99187

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		A. Porat et al., A 56-kDa Selenium-binding Protein Participates in Intra-Golgi Protein Transport; 19 Amer. Soc. for Biochem. & Mol. Bio. 14457-14465 (2000)			
		P. Chang et al., Isolation, Characterization, and Chromosomal Mapping of a Novel cDNA Clone Encoding Human Selenium Binding Protein; 64 J. Cellular Biochem., 217-224 (1997)			
		G. Chen et al. Reduced Selenium-Binding Protein 1 Expression Is Associated With Poor Outcome In Lung Adenocarcinomas; 202 J. Pathol. 321-329 (2004)			
		C. Giometti et al., Mouse Liver Selenium-Binding Protein Decreased In Abundance By Peroxisome Proliferators; 21 Electrophoresis 2162-2169 (2000)			
		L. Jamba et al., Isolation And Identification Of Selenium-Labeled Proteins In The Mouse Kidney; 16 Anticancer Research 1651-1658 (1996)			
		J. Lanfear et al., Different Patterns Of Regulation Of the Genes Encoding The Closely Related 56 kDa Selenium- and Acetaminophen-Binding Proteins In Normal Tissues And During Carcinogenesis 14 Carcinogenesis 335-340 (1993)			
		D. Medina, Mechanisms of Selenium Inhibition Of Tumorigenesis, 206 Advances In Experimental Medicine And Biology 465-472 (1986)			
		K. Miyaguchi, Localization Of Selenium-Binding Protein At The Tips Of Rapidly Extending Protrusions 121 Histochem Cell Biol 371-376 (2004)			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.